Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

41. Chest physiotherapy for pneumonia in children. Full Text available with Trip Pro

Chest physiotherapy for pneumonia in children. Pneumonia is a lung infection that causes more deaths in children aged under five years than any other single cause. Chest physiotherapy is widely used as adjuvant treatment for pneumonia. Physiotherapy is thought to help remove inflammatory exudates, tracheobronchial secretions, and airway obstructions, and reduce airway resistance to improve breathing and enhance gas exchange. This is an update of a review published in 2013.To assess (...) and GRADE to assess the quality of the evidence for each outcome.We included three new RCTs for this update, for a total of six included RCTs involving 559 children aged from 29 days to 12 years with pneumonia who were treated as inpatients. Pneumonia severity was described as moderate in one trial, severe in two trials, and was not stated in three trials. The studies assessed five different interventions: effects of conventional chest physiotherapy (3 studies, 211 children), positive expiratory

2019 Cochrane

42. Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial Full Text available with Trip Pro

Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial Pneumonia is the leading infectious killer of children. Rigorous evidence supporting antibiotic treatment of children with nonsevere fast-breathing pneumonia in low-resource African settings is lacking.To assess whether treatment with placebo for nonsevere fast-breathing pneumonia is substantively less effective than 3 days of treatment (...) with amoxicillin.This double-blind, 2-arm, randomized clinical noninferiority trial with follow-up of 14 days screened 1343 HIV-uninfected children aged 2 to 59 months with nonsevere fast-breathing pneumonia at outpatient departments of hospitals in Lilongwe, Malawi, Africa, between June 2016 and June 2017.Placebo or amoxicillin dispersible tablets administered twice daily for 3 days.The primary end point was the proportion of children failing treatment by day 4 with a relative noninferiority margin of 1.5 times

2019 EvidenceUpdates

43. A Multivariable Prediction Model for Pneumocystis jirovecii Pneumonia in Hematology Patients with Acute Respiratory Failure (Abstract)

A Multivariable Prediction Model for Pneumocystis jirovecii Pneumonia in Hematology Patients with Acute Respiratory Failure The incidence of Pneumocystis jirovecii pneumonia (PjP) is rising. Longer time to treatment is associated with higher mortality.To develop a multivariable risk prediction model for PjP diagnosis.In a prospective multicenter cohort of ICU patients with hematological malignancies and acute respiratory failure, factors associated with documented PjP were identified. The risk

2019 EvidenceUpdates

44. Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. Full Text available with Trip Pro

Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. The Hospital Readmissions Reduction Program (HRRP) has been associated with a reduction in readmission rates for heart failure (HF), acute myocardial infarction (AMI), and pneumonia. It is unclear whether the HRRP has been associated with change in patient mortality.To determine whether the HRRP was associated (...) with a change in patient mortality.Retrospective cohort study of hospitalizations for HF, AMI, and pneumonia among Medicare fee-for-service beneficiaries aged at least 65 years across 4 periods from April 1, 2005, to March 31, 2015. Period 1 and period 2 occurred before the HRRP to establish baseline trends (April 2005-September 2007 and October 2007-March 2010). Period 3 and period 4 were after HRRP announcement (April 2010 to September 2012) and HRRP implementation (October 2012 to March 2015

2018 JAMA

45. Pneumonia Vaccine for Adults: Is the efficacy as effective as the effort?

Pneumonia Vaccine for Adults: Is the efficacy as effective as the effort? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca Reviewed: August 27, 2018 Evidence Updated: Slight change to first systematic review ’s population and vaccine subtypes Bottom Line: No Change First Published: July 30, 2018 Pneumonia Vaccine for Adults: Is the efficacy as effective as the effort? Clinical Question: How effective is the pneumococcal vaccine in preventing pneumonia or other clinically important outcomes in adults? Bottom Line: At best, pneumococcal vaccines may prevent pneumonia for an additional 1 in 55 adults and 1 in 20 COPD

2018 Tools for Practice

46. Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia? (SRS Therapy)

Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia? (SRS Therapy) TAKE-HOME MESSAGE For adult patients with severe community-acquired pneumonia, corticosteroids reduce morbidity and mortality. For pediatric patients and adults with nonsevere community-acquired pneumonia, corticosteroids appear to reduce morbidity, but not mortality. Are Corticosteroids Bene?cial in the Treatment of Community-Acquired Pneumonia? EBEM Commentators Thomas Seagraves, MD Michael Gottlieb (...) , MD Department of Emergency Medicine Rush University Medical Center Chicago, IL Results Comparison of corticosteroids with control for community-acquired pneumonia. Outcome No. of Studies (No. of Participants) Relative Risk (95% CI) I 2 ,% Mortality (adults with severe CAP) 9 (995) 0.58 (0.40–0.84) 12 Mortality (adults with nonsevere CAP) 4 (868) 0.95 (0.45–2.00) 0 Early clinical failure (adults with severe CAP) 5 (419) 0.32 (0.15–0.70) 74 Early clinical failure (adults with nonsevere CAP) 2 (905

2018 Annals of Emergency Medicine Systematic Review Snapshots

47. Omadacycline (Nuzyra) - To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

Omadacycline (Nuzyra) - To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections Drug Approval Package: NUZYRA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NUZYRA Company: Paratek Pharmaceuticals, Inc. Application Number: 209816 & 209817 Approval Date: 10/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

2018 FDA - Drug Approval Package

48. Guideline Adoption for Community-Acquired Pneumonia in the Outpatient Setting

Guideline Adoption for Community-Acquired Pneumonia in the Outpatient Setting Community-acquired pneumonia (CAP) is diagnosed in >1.2 million children in outpatient settings and emergency departments (EDs) each year in the United States. 1, 2 Most antibiotic prescribing for CAP occurs in the outpatient setting. In 2011, members of the Pediatric Infectious Diseases Society and Infectious Diseases Society of America published an evidence-based guideline for the management of CAP in children (...) . The authors of the recommendations encourage prescribing narrow Guideline Adoption for Community-Acquired Pneumonia in the Outpatient Setting Lilliam Ambroggio, PhD, MPH, a , b, c Colleen Mangeot, MS, b Eileen Murtagh Kurowski, MD, MS, c , d Camille Graham, MD, c , e , f Paul Korn, MD, g Marcie Strasser, MD, h Charles Cavallo, MD, i Katherine Brady, MD, j Suzanne Campanella, MPH, a Caitlin Clohessy, BA, a William B. Brinkman, MD, MEd, MSc, c , e Samir S. Shah, MD, MSCE a , c , k BACKGROUND: The Pediatric

2018 American Academy of Pediatrics

49. Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study Full Text available with Trip Pro

Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant (...) Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary antigen test (30.1%), pneumococcal urinary antigen test (30.0%), viral testing (14.9%), acute-phase serology (8.8%), bronchoalveolar lavage culture (8.4%) and pleural fluid culture (3.2%). A pathogen

2018 ERJ open research

50. Prevention of ventilator-associated pneumonia in newborns. (Abstract)

Prevention of ventilator-associated pneumonia in newborns. The aim of the study is to optimize the prevention of the development of ventilator-associated pneumonia in newborns by developing a method for tracheal rehabilitation and assessment of its effectiveness.Materials and methods: A prospective cohort randomized clinical study was organized, particularly artificial ventilation of the lungs was conducted on 90 newborns. Patients were divided into two groups. In the main group (n = 50 (...) tracheal sanation on the outer surface of the intubation tube in newborns units that undergo artificial ventilation of the lungs exhibit high efficiency against the main types of microorganisms that are dangerous from the point of view of the development of ventilator-associated pneumonia. The use of prophylactic tracheal sanitization in newborns - patients of neonatal intensive care units, which undergoes artificial ventilation of the lungs, can significantly lower the frequency of the implementation

2018 Wiadomosci lekarskie (Warsaw, Poland : 1960) Controlled trial quality: uncertain

51. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin (...) with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI, -∞ to 14.5%]; P = .90 for noninferiority). Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group.Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared

2018 JAMA Controlled trial quality: predicted high

52. Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. Full Text available with Trip Pro

Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. Community-acquired pneumonia (CAP) is a lung infection that can be acquired during day-to-day activities in the community (not while receiving care in a hospital). Community-acquired pneumonia poses a significant public health burden in terms of mortality, morbidity, and costs. Shorter antibiotic courses for CAP may limit treatment costs and adverse effects

2018 Cochrane

53. Performance of the CURB-65 Score in Predicting Critical Care Interventions in Patients Admitted With Community-Acquired Pneumonia (Abstract)

Performance of the CURB-65 Score in Predicting Critical Care Interventions in Patients Admitted With Community-Acquired Pneumonia Confusion, uremia, elevated respiratory rate, hypotension, and aged 65 years or older (CURB-65) is a clinical prediction rule intended to stratify patients with pneumonia by expected mortality. We assess the predictive performance of CURB-65 for the proximal endpoint of receipt of critical care intervention in emergency department (ED) patients admitted (...) with community-acquired pneumonia.We performed a retrospective analysis of electronic health records from a single tertiary center for ED patients admitted as inpatients with a primary diagnosis of pneumonia from 2010 to 2014. Patients with a history of malignancy, tuberculosis, bronchiectasis, HIV, or readmission within 14 days were excluded. We assessed the predictive accuracy of CURB-65 for receipt of critical care interventions (ie, vasopressors, large-volume intravenous fluids, invasive catheters

2018 EvidenceUpdates

54. Pneumonia induced by benzodiazepines

Pneumonia induced by benzodiazepines Page xvi · MED CHECK - TIP August 2018/ Vol.4 No.11 -The Informed Prescriber C N o 11 M ED HECK A u g u s t 2 0 1 8 What we learned from epidemiological studies on drug-induced pneumonia Japanese Guideline for Hypertension is for disease mongering Editorial What we learned from epidemiological studies on drug-induced pneumonia New Products A new cholesterol lowering agent: lomitapide is highly toxic Reviews Japanese Guideline for Hypertension is for disease (...) mongering Medical checkups create “patients” and shorten their lifespan by “treatment” Adverse Reactions Pneumonia induced by benzodiazepines Evidence shows causal relations CONTENTS (August 2018, Vol. 4, No. 11 ) 16 17 20 24 Volume 4 Page 16 · MED CHECK - TIP August 2018/ Vol.4 No.11 What we learned from epidemiological studies on drug-induced pneumonia It is well known that corticosteroids and cytotoxic anticancer agents cause infections. The labels of non- steroidal anti-inflammatory drugs (NSAIDs

2018 Med Check - The Informed Prescriber

55. Pneumonia

Pneumonia Top results for pneumonia - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pneumonia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

56. Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study Full Text available with Trip Pro

Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study The diagnosis of pneumonia is challenging. Our objective was to assess whether low-dose computed tomography (LDCT) modified the probability of diagnosing pneumonia in elderly patients.We prospectively included patients aged over 65 years with a suspicion of pneumonia treated with antimicrobial therapy (AT). All patients had a chest radiograph and LDCT within 72 h (...) of inclusion. The treating clinician assessed the probability of pneumonia before and after the LDCT scan using a Likert scale. An adjudication committee retrospectively rated the probability of pneumonia and was considered as the reference for diagnosis. The main outcome was the difference in the clinician's pneumonia probability estimates before and after LDCT and the proportion of modified diagnoses which matched the reference diagnosis (the net reclassification improvement (NRI)).A total of 200

2018 EvidenceUpdates

57. Pneumonia

Pneumonia Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history

2018 Trip Evidence Maps

58. Identification of Pathogenicity-Associated Loci in Klebsiella pneumoniae from Hospitalized Patients Full Text available with Trip Pro

Identification of Pathogenicity-Associated Loci in Klebsiella pneumoniae from Hospitalized Patients Despite insights gained through experimental models, the set of bacterial genes important for human infection is unclear for many of our most threatening pathogens. Klebsiella pneumoniae is a leading cause of health care-associated infections (HAIs) and commonly colonizes hospitalized patients, but the factors that determine whether a particular isolate causes disease or remains a colonizer (...) are poorly understood. To identify bacterial genes associated with K. pneumoniae infection, a case-control study was performed comparing infected and asymptomatic colonized patients. Comparative bacterial genomics was combined with a conditional logit model that identified patient factors differentiating cases from controls. This method identified five gene loci associated with infection after adjustment for patient factors, including a psicose sugar utilization locus that was validated as a fitness

2018 mSystems

59. Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia Full Text available with Trip Pro

Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia A summary of the evidence and recommendations made in the ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia http://ow.ly/S3zA30iZfLa.

2018 ERJ open research

60. Treating nosocomial pneumonia: what's new Full Text available with Trip Pro

Treating nosocomial pneumonia: what's new A detailed and comprehensive summary of the ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia, published in ERJ Open Research, will assist clinicians in their tasks http://ow.ly/XC7N30k8Jhu.

2018 ERJ open research